Novo Nordisk has been on the hunt for differentiated weight problems medicine that would complement its blockbuster GLP-1 agonist, Wegovy. It’s discovered a contender with preclinical information indicating it may well result in larger weight reduction as a part of a drug mixture and in addition forestall weight regain after remedy with the GLP-1 treatment is stopped.
The Danish pharmaceutical big is licensing world rights to LX9851, a drug found and developed by Lexicon Prescription drugs, the businesses introduced Friday. LX9851 is an oral small molecule that blocks Acyl-CoA Synthetase 5 (ACSL5), an enzyme that performs a key function in a metabolic pathway regulating fats accumulation and vitality steadiness. In keeping with Lexicon, this molecule can also activate the ileal brake, a suggestions mechanism that slows motion of meals by means of the gastrointestinal system and promotes emotions of satiety.
The Woodlands, Texas-based Lexicon has been learning this LX9851 as a standalone remedy and together with GLP-1 agonists corresponding to semaglutide, the primary ingredient in Novo Nordisk’s Wegovy. On the Weight problems Week 2024 convention final November, Lexicon offered preclinical outcomes from a take a look at of LX9851 together with semaglutide. Lexicon stated this drug pairing led to vital discount in weight, meals consumption, and fats mass in comparison with semaglutide alone. Further outcomes confirmed that after dosing of semaglutide was stopped, the Lexicon drug mitigated weight regain and had constructive results on the liver.
In keeping with the phrases of the license settlement, Lexicon remains to be chargeable for finishing the preclinical analysis that may help an investigational new drug (IND) software for the ACLS5 inhibitor. Novo Nordisk will tackle accountability for that IND submitting in addition to additional growth, manufacturing, and commercialization of the drug.
The deal provides the pharma big world rights to LX9851 for all indications. Novo Nordisk has dedicated to pay as much as $75 million in upfront and near-term milestone funds. Reaching further milestones might convey the monetary outlay to $1 billion. If the analysis leads to a commercialized product, Lexicon will obtain royalties from Novo Nordisk’s gross sales of the drug.
To Leerink Companions, the deal validates Lexicon’s weight problems platform whereas offering the biotech with monetary flexibility to give attention to its different cardiometabolic medicine. In a observe despatched to traders, analyst Roanna Ruiz stated the ACLS5 inhibition supplied by LX9851 enhances GLP-1 agonism, with preclinical outcomes displaying about 20% larger weight reduction when added to semaglutide in comparison with semaglutide alone. Ruiz added that the molecule’s potential to stop the load regain after discontinuing GLP-1 use was notably compelling as a result of regaining weight continues to be a serious hurdle in weight problems administration.
“Large image, the deal aligns with Novo’s technique to take care of dominance within the weight problems house by including complementary mechanisms to pair with their GLP-1 franchise, and we look ahead to extra updates from the collaboration going ahead,” Ruiz stated.
The LX9851 licensing settlement is the newest in a string of offers struck by Novo Nordisk to develop its metabolic medicines pipeline. Earlier this week, the pharma big agreed to pay United Biotechnology $200 million up entrance for rights to an early scientific peptide drug engineered to activate three targets to immediate weight reduction.
Photograph: Getty Photographs